

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030

CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2023

(Rs. in Lakhs)

	Particulars	3 months ended 30.06.2023	Preceding 3 months ended 31.03.2023	Corresponding 3 months ended 30.06.2022	Year ended 31.03.2023
		(Unaudited)	(Unaudited) (Refer Note 2)	(Unaudited)	(Audited) (Refer Note 4)
	Continuing operations				
	Income				
1	Revenue from operations	76166	78745	74510	325172
2	Other income	3644	2766	2761	10066
3	Total Income (1+2)	79810	81511	77271	335238
	Expenses				
	(a) Cost of materials consumed	15841	9410	15378	42748
	(b) Purchases of stock-in-trade	17420	17779	27160	78843
	(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(3649)	7290	(13848)	6896
	(d) Employee benefits expense	16500	14884	15122	59499
	(e) Finance costs	28	65	68	181
	(f) Depreciation and amortisation expense	1636	1718	1582	6577
	(g) Other expenses	15666	12408	15806	56757
4	Total expenses	63442	63554	61268	251501
5	Profit before exceptional items and tax (3-4)	16368	17957	16003	83737
6	Exceptional items [credit/(charge)] (Refer Note 3)	1730	1040	-	(97)
7	Profit before tax (5+6)	18098	18997	16003	83640
8	Tax expense				
	(a) Current tax	5323	5730	4727	24713
	(b) Deferred tax	(450)	(76)	(347)	(1837)
9	Profit for the period/year from continuing operations (7-8)	13225	13343	11623	60764
	Discontinued operations				
10	Profit before tax from discontinued operations (Refer Note 4)	-	-	413	413
11	Tax expense of discontinued operations (Refer Note 4)	-	-	108	108
12	Profit from discontinued operations after taxes (10-11)	-	-	305	305
13	Profit for the period (9+12)	13225	13343	11928	61069

GlaxoSmithKline Pharmaceuticals Limited

Registered Office: Dr. Annie Besant Road, Mumbai - 400 030
CIN: L24239MH1924PLC001151 Tel No: +91 22 2495 9595 Fax No: +91 22 24959494

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2023

(Rs. in Lakhs)

	Particulars	3 months ended 30.06.2023	Preceding 3 months ended 31.03.2023	Corresponding 3 months ended 30.06.2022	Year ended 31.03.2023
		(Unaudited)	(Unaudited) (Refer Note 2)	(Unaudited)	(Audited) (Refer Note 4)
14	Other comprehensive income				
	(i) Items that will not be reclassified to profit or loss	-	(180)	-	(807)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	45	-	203
15	Total comprehensive income for the period (13+14)	13225	13208	11928	60465
16	Total comprehensive income for the period attributable to owners of the Group	13225	13208	11928	60465
	Paid-up equity share capital (face value per share Rs. 10)	16941	16941	16941	16941
	Other equity				157187
	Earnings per share (EPS) (of Rs. 10 each) (for continuing operations)				
	Basic and diluted EPS before Exceptional items (Rs.)	7.04	7.41	6.86	35.90
	Basic and diluted EPS after Exceptional items (Rs.)	7.81	7.88	6.86	35.87
	Earnings per share (EPS) (of Rs. 10 each) (for discontinued operations)				
	Basic and diluted EPS for discontinued operations (Rs.)	-	-	0.18	0.18
	Earnings per share (EPS) (of Rs. 10 each) (for continuing and discontinued operations)				
	Basic and diluted EPS before Exceptional items (Rs.)	7.04	7.41	7.04	36.08
	Basic and diluted EPS after Exceptional items (Rs.)	7.81	7.88	7.04	36.05
		Not Annualised			

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 26th July, 2023. The Statutory Auditors have carried out a limited review of the consolidated financial results for the quarter ended 30th June, 2023.
2. The figures for the 3 months ended 31st March, 2023 are the balancing figures between the audited figures in respect of full financial year and the published year to date figures upto the third quarter of the financial year ended 31st March, 2023.
3. Exceptional items credit for the quarter ended 30th June, 2023 of Rs.1730 lakhs (Quarter ended 31st March, 2023 Rs. 1040 lakhs) is on account of profit on sale of surplus residential properties. Exceptional items charge for the year ended 31st March, 2023 of Rs.97 lakhs comprises of profit on sale of surplus residential properties Rs. 964 lakhs; additional charge of Rs. 1137 lakhs on account of restructuring of the commercial functions and other reversals credit of Rs. 76 lakhs.
4. The Board of Directors of the Parent Company had approved the transfer of the trademarks pertaining to 'Iodex' and 'Ostocalcium' brands ("Brands") in India along with legal, economic, commercial and marketing rights of such brands and other identified assets to GlaxoSmithKline Asia Private Limited during the year ended 31st March, 2022. Consequently, the transfer of brands and profits arising from sale of products as per the terms of contract had been disclosed as Discontinued Operations in accordance with Ind AS 105 "Non-Current Assets Held for Sale and Discontinued Operations".
5. The Group has only one reportable segment which is Pharmaceuticals. Accordingly, no separate disclosures of segment information have been made.
6. Previous periods' figures have been re-grouped / re-classified wherever necessary.

26th July, 2023

By Order of the Board



Bhushan Akshikar
Managing Director
DIN: 09112346

